Brand Intelligence Graph
Company Overview
About Retro Biosciences
Retro Biosciences is the largest-funded pure-play longevity company in history, raising $1 billion in Series A financing at a $5 billion valuation with Sam Altman (OpenAI CEO) as a primary backer. The company is pursuing cellular reprogramming, autophagy enhancement, and plasma factor therapeutics in parallel — a multi-pronged approach to extending healthy human lifespan by targeting the cellular hallmarks of aging simultaneously.
Business Model & Competitive Advantage
The $5B valuation with zero clinical data reflects extraordinary conviction from tech-founder capital that biological aging is fundamentally a solvable engineering problem. Retro is preparing its first human trial, targeted to launch in Australia, which will be a pivotal test of the cellular reprogramming hypothesis in vivo. The company works with leading academic researchers in aging biology and benefits from Sam Altman's network for scientific talent recruitment.
Competitive Landscape 2025–2026
Retro's approach is distinctively ambitious: rather than targeting a single disease or aging pathway, it is attempting to reverse the fundamental epigenetic aging clock that drives age-related decline across all tissues. If successful, this would represent a paradigm shift from disease treatment to genuine biological rejuvenation — a category of medicine that does not yet have an approved product anywhere in the world.
Key Differentiators
Emerging Innovator
Retro Biosciences is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Retro Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Retro Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Retro Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Retro Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →